K-ras as a target for lung cancer therapy

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

K-ras is currently accepted to be the most frequently mutated oncogene in non-small cell lung cancer. In addition, tumors harboring mutant K-ras seem to be refractory to most available systemic therapies, making K-ras an attractive target for cancer therapy. The complexity of K-ras signaling presents many opportunities for therapeutic targeting. A number of different approaches aimed at abrogating K-ras activity have been explored in clinical trials. Several of the putative K-ras-directed therapeutic agents tested have demonstrated clinical activity. However, many of these agents have multiple targets, and their antitumor effects may not be due to K-ras inhibition. To date, no selective, specific inhibitor of the K-ras pathway is available for routine clinical use.

Original languageEnglish (US)
Pages (from-to)S160-S163
JournalJournal of Thoracic Oncology
Volume3
Issue number6 SUPPL 2
DOIs
StatePublished - Jun 2008

    Fingerprint

Keywords

  • K-ras
  • Mitogen-activated protein kinase
  • NSCLC
  • Raf kinase

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this